Articles tagged with: ART
Featured, Headline, News »
Tibotec Pharmaceuticals and Gilead Sciences have agreed to develop a new once-daily combination antiretroviral pill that combines the protease inhibitor Prezista with the investigational booster cobicistat.
In addition, the companies are currently in negotiations to develop a second pill combining Prezista, cobicistat, Emtriva, and an investigational new form of Viread called GS 7340.
“We are excited to be able to study and develop Prezista with an alternative boosting agent in a combination product which has the potential to reduce the number of tablets patients take,” said Dr. Johan Van Hoof,…
News »
High Bar Set For New AIDS Drugs – Thirty years after the discovery of the HIV virus, 31 drugs are currently on the market to help make HIV a manageable disease. In particular, Gilead Sciences’ once-daily pill Atripla (efavirenz/emtricitabine/tenofovir) is the most widely used AIDS drug. However, such a success has now set the bar high for new drugs. Fewer anti-HIV drugs are in the pipeline in recent years, and several investigational drugs have failed to outperform the current options. Although most HIV-positive individuals are able to manage their disease with the available treatments, the lack of new treatments is leaving some worried that HIV-positive individuals may face the possibility of their virus developing resistance to the current arsenal of drugs. For more information, please visit the San Francisco Chronicle article.
AIDSinfo Releases Adult And Adolescent Antiretroviral Guidelines In Web-Friendly Format – AIDSinfo, a website run by the U.S. Department of Health and Human Services, now offers a way to view the latest antiretroviral guidelines for adults and adolescents in both web-friendly and printer-friendly formats. Pediatric and other HIV-related guidelines are available on the site in a printer-friendly format. For more information, please visit the AIDSinfo website.
Phase 3 Clinical Trial Tests Truvada Plus Rilpivirine Combination Pill Versus Atripla In Previously Untreated HIV-Positive Adults – Gilead Sciences is currently recruiting participants for a Phase 3 study testing the efficacy and safety of a single tablet regimen of Truvada (emtricitabine/ tenofovir) plus rilpivirine (TMC278) compared to Atripla (efavirenz/emtricitabine/tenofovir). HIV-positive adults who have not been previously treated with antiretroviral therapy may be eligible. Participants will receive either a once-daily tablet of Truvada/rilpivirine or Atripla for 96 weeks. At 48 weeks, viral load (amount of HIV RNA) and CD4 (white blood) cell counts will be assessed. At 96 weeks, CD4 cell counts will be reassessed. For more information, please visit the U.S. Clinical Trials Registry.
Headline, News »
This article is the first in a two-part series discussing Dr. Patrick Yeni’s presentation at the 18th Conference on Retroviruses and Opportunistic Infections, entitled “15 Years of HAART: What Does the Future Hold?” The first article discusses new antiretrovirals and treatments for HIV. The second article discusses ongoing research efforts to find a cure for HIV.
Highly active antiretroviral therapy has improved over the past 15 years and is now more effective, less toxic, and easier to take than earlier treatment regimens. However, there is still room for improvement,…
Espanol »
Este artículo es el primero de una serie de dos en los que se debate sobre la presentación del Dr. Patrick Yeni en la “18ª Conferencia Sobre Retrovirus e Infecciones Oportunistas”, titulada “15 años de la HAART: ¿qué nos depara el futuro?” Este primer artículo analiza los nuevos antirretrovirales y tratamientos para VIH. El segundo artículo habla de los esfuerzos de investigación en curso destinados a encontrar una cura para el VIH.
La terapia antirretroviral altamente activa (HAART, por sus siglas en inglés) ha mejorado en los últimos 15 años…
Featured, Headline, News »
Results of a recent large study indicate that interruptions in antiretroviral therapy limit CD4 cell recovery and increase the risk of opportunistic infections and death in people with HIV.
The study results support the findings from previous shorter-term studies showing that treatment interruptions are highly detrimental to people with HIV.
Based on these findings, the researchers suggested that doctors initiate antiretroviral therapy early in HIV patients, avoid treatment interruptions or keep them as short as possible, and decrease viral loads as much as possible.
Antiretroviral therapy consists of at least…